Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix

Abstract

Cervical cancer is caused by persistent infection with high-risk human papillomavirus (hrHPV). Cytology-based national screening programs have reduced the incidence and mortality of cervical cancer. Different hrHPV subtypes have different carcinogenic potentials. This study evaluated the distribution of different types of hrHPV relative to age in cervical cancer and its precursor lesions. HPV testing was performed between November 2018 and February 2020 using the Abbott RealTime high-risk HPV assay on an Abbott m2000sp instrument. This assay separately detects HPV-16, HPV-18, and a pool of 12 additional hrHPV types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68). The study included 652 women with HPV samples and biopsies of the cervix or histology samples obtained during surgery. In all, 30.8% (95% CI, 27.3–34.6%) were HPV-negative. Among HPV-positive women, HPV-16, HPV-18, and “HPV other” types were found in 33.5, 4.4, and 49.4%, respectively. Cervical intraepithelial neoplasia (CIN) 3/high-grade squamous intraepithelial lesions (HSILs) in women\u2009≤\u200934 years were positive for HPV-16 in 54.5% of cases and in those\u2009≥\u200935 years in 45.4% of cases. Among women with cervical cancer, 75.8% were infected with HPV-16 or had coinfection with HPV-16 and “HPV other”. HPV-16 is the most common type of hrHPV in HSIL\u2009+\u2009lesions. It is more common in women diagnosed with CIN 3/HSIL who are aged\u2009≤\u200935 and is decreasing with age. Therefore, women age\u2009≥\u200935 with persistent infection with this type of hrHPV need careful surveillance, as they are at high risk of progression to cervical cancer.